Cancer analgesic

29 Sep 1986
News

Executive Summary

Natl. Institute on Drug Abuse Director Charles Schuster told a meeting of the Natl. Advisory Council on Drug Abuse Sept. 16 that an NIAD grantee, Tony Yaksh, Mayo Clinic, "has shown that an opioid peptide, D-Ala2-DO-Leu5-enkephalin (DADL), binds to the brain's delta opiate receptor to produce analgesia in cancer patients." Schuster said the discovery is "an important step toward the development of a non-addictive pain-killer that could replace morphine".

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS010780

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS010780

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Cancer analgesic

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert